Matinas BioPharma to Ring NYSE Opening Bell® on May 6, 2019

BEDMINSTER, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has been invited to ring the NYSE Opening Bell® on Monday, May 6^th, 2019 at 9:30 AM E.T., to commemorate a transformational period for the company culminating in its recent successful $32 million institutional financing, which positions the company to capitalize on several upcoming milestones.  In honor of this special occasion and in recognition of his significant contributions to the pharmaceutical industry over the course of a storied career, Herbert J. Conrad, Chairman of the Matinas Board, will ring the bell signifying the start of the day’s trading session.  Mr. Conrad will be joined on the bell podium by Chief Executive Officer, Jerome D. Jabbour, and other members of the Matinas’ management team and board of directors. 

“Ringing the NYSE Opening Bell® on essentially the second anniversary of our listing on the NYSE, and following a recent period of significant progress and interest in our company, serves as a poignant reminder of just how much Matinas has grown and evolved over the past two years,” commented Jerome D. Jabbour, Chief Executive Officer.  “As a company focused on improving the lives of patients with a potential best-in-class prescription omega-3 in a new multi-billion dollar market and developing a disruptive drug delivery platform with current exciting applications in the anti-infective and gene therapy spaces with the additional potential for far-broader impact, we are extremely proud of the progress we have made and believe we are uniquely positioned to potentially drive significant value creation as we advance our exciting clinical programs.  Finally, we are also thrilled that our Chairman, Herb Conrad, will have the honor of ringing the Opening Bell®.  His impact on the pharmaceutical industry over the course of his career has been far-reaching, highlighted by roles as President of the Pharmaceuticals Division of Hoffmann-LaRoche Inc. and as Chairman of Pharmasset through its acquisition by Gilead Sciences Inc.  We are fortunate that Matinas will continue to benefit from his guidance and strategic vision as we build additional shareholder value and develop important products which, if approved, have the potential to benefit millions of patients.”

In addition to live television coverage of the ceremony, the New York Stock Exchange will stream the Opening Bell®  ringing on its website: https://www.nyse.com/bell. The bell ringing is scheduled for 9:26 AM – 9:30 AM E.T.  A video of the bell ringing will also be archived on the same page after the livestream.  Photos and video of the NYSE Bell Ringing Ceremony also will be available courtesy of the NYSE on Facebook (NYSE), on Twitter (@NYSE), on YouTube (nysetv1) and from media@theice.com.

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.

Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT9001 and MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

Source: Matinas BioPharma Holdings, Inc.

Released May 2, 2019